Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BJSE:920047's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.25 * Ranked among companies with meaningful Forward Dividend Yield % only.
Beijing Northland Biotech Co (BJSE:920047) Forward Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Beijing Northland Biotech Co Forward Dividend Yield % Related Terms
BJSE:920047 vs VRTX, REGN, MRNA: Forward Dividend Yield % Comparison
For the Biotechnology subindustry, Beijing Northland Biotech Co's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beijing Northland Biotech Co Forward Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Beijing Northland Biotech Co's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Beijing Northland Biotech Co's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Beijing Northland Biotech Co (BJSE:920047) has a Forward Dividend Yield % of 0.00% as of Sep. 09, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Beijing Northland Biotech Co and its competitors. According to the industry distribution chart, Beijing Northland Biotech Co ranks #999999 out of 147 companies in the Biotechnology industry.
Is Beijing Northland Biotech Co's Forward Dividend Yield % too high?
Beijing Northland Biotech Co's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Beijing Northland Biotech Co ranks #999999 out of 147 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Beijing Northland Biotech Co has a GF Score™ of 59/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Beijing Northland Biotech Co's Forward Dividend Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Beijing Northland Biotech Co ranks #999999 out of 147 companies for Forward Dividend Yield %. This places Beijing Northland Biotech Co in the lower half of its industry. The industry median Forward Dividend Yield % is 1.25. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.25, based on 147 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Beijing Northland Biotech Co and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beijing Northland Biotech Co's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Northland Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Beijing Northland Biotech Co (BJSE:920047) is currently considered Fairly Valued. The stock's GF Value™ is ¥15.45, compared to a current price of ¥15.57 — trading 0.8% above its estimated fair value. The current Forward Dividend Yield % is 0.00%. Beijing Northland Biotech Co's overall GF Score™ is 59/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Beijing Northland Biotech Co (BJSE:920047), the current Forward Dividend Yield % is 0.00% as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beijing Northland Biotech Co (BJSE:920047) Overvalued in 2026?
Based on GuruFocus' analysis, Beijing Northland Biotech Co stock appears to be overvalued.
The current stock price of ¥15.57 is trading 0.8% above its estimated GF Value™ of ¥15.45.
GuruFocus considers Beijing Northland Biotech Co to be Fairly Valued.
Key valuation signals for BJSE:920047:
Forward Dividend Yield %: 0.00%
GF Value™: ¥15.45 vs. price of ¥15.57 (0.8% above fair value)
No single metric tells the full story. See the BJSE:920047 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beijing Northland Biotech Co Ltd is engaged in technology transfer, technical services, production and sales of ophthalmic drugs, contract manufacturing, and contract research and development. The company's independently developed biopharmaceutical, NL003, has completed Phase III clinical trials this year.
59GF Score
Get the complete analysis for BJSE:920047
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJSE:920047 has been successfully added to your 
